Abstract
Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver function and correlates with central adiposity, obesity, insulin resistance, the metabolic syndrome and type 2 diabetes mellitus. The pathological spectrum of NAFLD ranges from fatty liver to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and even hepatocellular carcinoma. Though NAFLD and NASH are becoming a major public health problem, ethical constraints on obtaining human liver tissue limit the interpretability of the data and the ability to delineate cause and effect from complex, interactive disease pathogenic pathways. Animal models of NASH can provide critical information leading to identify potential drug targets and to understand their molecular mechanisms, and are platforms for compound screening in drug development and for the assessment of novel therapeutic strategies. This review is aimed to offer an updated overview of the nutritional, genetic and pharmacologic animal models of NASH. Though the information derived from these models has clear relevance for the comprehension of the molecular basis of human disease, most of them fail to reproduce the full spectrum of liver pathology and the metabolic context that characterizes human NASH. Consequently, it is necessary to establish animal models that can best mimic the actual etiology, progression, and pathogenesis of the disease, and prove effectiveness for examining and selecting compounds with potential therapeutic benefit in NASH.
Keywords: Animal models, atherogenesis, dietary models, genetic models, non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease (NAFLD), syndrome, diabetes mellitus, hepatocellular carcinoma, lobular inflammation
Current Medicinal Chemistry
Title: Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
Volume: 19 Issue: 9
Author(s): C. C. Almonacid-Urrego, S. Sanchez-Campos, M. J. Tunon and J. Gonzalez-Gallego
Affiliation:
Keywords: Animal models, atherogenesis, dietary models, genetic models, non-alcoholic steatohepatitis, Non-alcoholic fatty liver disease (NAFLD), syndrome, diabetes mellitus, hepatocellular carcinoma, lobular inflammation
Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver function and correlates with central adiposity, obesity, insulin resistance, the metabolic syndrome and type 2 diabetes mellitus. The pathological spectrum of NAFLD ranges from fatty liver to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and even hepatocellular carcinoma. Though NAFLD and NASH are becoming a major public health problem, ethical constraints on obtaining human liver tissue limit the interpretability of the data and the ability to delineate cause and effect from complex, interactive disease pathogenic pathways. Animal models of NASH can provide critical information leading to identify potential drug targets and to understand their molecular mechanisms, and are platforms for compound screening in drug development and for the assessment of novel therapeutic strategies. This review is aimed to offer an updated overview of the nutritional, genetic and pharmacologic animal models of NASH. Though the information derived from these models has clear relevance for the comprehension of the molecular basis of human disease, most of them fail to reproduce the full spectrum of liver pathology and the metabolic context that characterizes human NASH. Consequently, it is necessary to establish animal models that can best mimic the actual etiology, progression, and pathogenesis of the disease, and prove effectiveness for examining and selecting compounds with potential therapeutic benefit in NASH.
Export Options
About this article
Cite this article as:
C. Almonacid-Urrego C., Sanchez-Campos S., J. Tunon M. and Gonzalez-Gallego J., Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462586
DOI https://dx.doi.org/10.2174/092986712799462586 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Disease: A New Progenitor Biology
Current Vascular Pharmacology The G Protein β3 Subunit Gene (GNB3) 825T Allele - a Thrifty Genotype
Current Genomics Evidence on the Protective Role of High-Density Lipoprotein (HDL) in HIV-Infected Individuals
Current Vascular Pharmacology Community-Acquired Pneumonia and Outcome: The Importance of Genetics
Current Respiratory Medicine Reviews Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Diagnostic Approach to Mitochondrial Disorders: the Need for a Reliable Biomarker
Current Molecular Medicine Heterogeneity in the CD4 T Cell Compartment and the Variability of Neonatal Immune Responsiveness
Current Immunology Reviews (Discontinued) Subclinical Hypothyroidism and Cognitive Dysfunction in the Elderly
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycation and Antioxidants: Hand in the Glove of Antiglycation and Natural Antioxidants
Current Protein & Peptide Science Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results Beyond Symptom Control
Current Clinical Pharmacology Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design Microglia NLRP3 Inflammasomes Activation Involving Diabetic Neuroinflammation in Diabetic Mice and BV2 Cells
Current Pharmaceutical Design Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Development of Sol-Gel Hybrid Materials for Whole Cell Immobilization
Recent Patents on Biotechnology Non-Systemic Drugs: A Critical Review
Current Pharmaceutical Design Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
Current Pharmaceutical Design Para-Tyrosine Supplementation Improves Insulin- and Liraglutide- Induced Vasorelaxation in Cholesterol-Fed Rats
Protein & Peptide Letters FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism
Endocrine, Metabolic & Immune Disorders - Drug Targets Chemical Changes in Dairy Products Resulting from Cholesterol Removal Using Beta Cyclodextrins
Current Nutrition & Food Science